Point of Care Testing 2014:
Applications for Microfluidic Technologies
What strategies could new players use to enter the Point of Care market?
MICROFLUIDIC-BASED POINT OF CARE IS NOW A MUST-HAVE FOR DIAGNOSTIC COMPANIES. IS THE MERGERS & ACQUISITIONS SEASON OVER?
The Point of Care (POC) market’s contribution to in vitro diagnostic is poised to increase from 13% to 17% over the next five years, leading to a market of around $30B in 2019.
Different types of Point of Care tests are available on the market. Whereas simple lateral flow tests work perfectly without fluid management technology, microfluidics is necessary when test complexity increases. Indeed, microfluidics is an enabling technology allowing miniaturization and integration of laboratory protocols into portable devices.
POC testing based on microfluidic technology is expected to grow sharply, from $1.6B in 2013 to $5.6B in 2019, at a CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, Abbott Point of Care, BD Diagnostics, Cepheid, Abaxis, etc.) have realized the potential of rapid molecular diagnostic testing. Indeed, several successful Point of Care products based on microfluidic technology have been launched in the past few years. Access to microfluidic technologies for diagnostic companies often passes through acquisitions, as this reduces the technology development risk and increases reactivity. The most recent acquisition was that of IQuum by Roche for $275M in April 2014.
This new Yole Développement report describes how mergers and acquisitions will decrease in volume but increase in value.
Based on a complete analysis of the last three years’ developments, we have been able to draw effective conclusions. Despite slower than expected growth in 2012, we explain why strong future growth is still likely.
More information on that report at http://www.i-micronews.com/reports/Point-Care-Testing-2014-Microfluidic-Technologies/4/435/